



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

January 12, 2017

BTL Industries, Inc.  
Mr. David Chmel  
47 Loring Drive  
Framingham, Massachusetts 01702

Re: K163176

Trade/Device Name: Exilis XP II

Regulation Number: 21 CFR 878.4400

Regulation Name: Electrosurgical cutting and coagulation device and accessories

Regulatory Class: Class II

Product Code: PBX

Dated: December 19, 2016

Received: December 22, 2016

Dear Mr. Chmel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely,

**Jennifer R. Stevenson -S**

For Binita S. Ashar, M.D., M.B.A., F.A.C.S.  
Director  
Division of Surgical Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

# K163176

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Food and Drug Administration

Form Approved: OMB No. 0910-0120  
Expiration Date: January 31, 2017  
See PRA Statement below.

## Indications for Use

510(k) Number (if known)

K163176

Device Name

Exilis XP II

Indications for Use (Describe)

The Exilis XP II RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The Exilis XP II massage device is intended to provide a temporary reduction in the appearance of cellulite.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*



BTL Industries

**K163176**

## **510(k) Summary**

### **General Information**

Sponsor: BTL Industries, Inc.  
47 Loring Drive  
Framingham, MA 01702  
Tel: [+1-866-285-1656](tel:+1-866-285-1656)  
Fax: +1-888-499-2502

Applicant: BTL Industries, Inc.  
47 Loring Drive  
Framingham, MA 01702  
Tel: [+1-866-285-1656](tel:+1-866-285-1656)  
Fax: +1-888-499-2502

Contact Person: David Chmel  
BTL Industries, Inc.  
[chmel@btlnet.com](mailto:chmel@btlnet.com)

Summary Preparation  
Date: 27 October 2016

### **Device Names**

Trade/Proprietary Name: Exilis XP II

Primary Classification Name: Massager, Vacuum, Radio Frequency Induced Heat

Classification Regulation: 878.4400

Product Code: PBX

### **Legally Marketed Predicate Devices**

The Exilis XP II system is a state-of-the-art high-frequency energy device with accessories, and is substantially equivalent to the current product that is already cleared for USA distribution under the following 510(k) Premarket Notification number:

- Exilis XP (K143040)

### **Product Description**

Subject of the submission is approval of design changes, improvement of the device ergonomics, hygiene and cleaning through addition of exchangeable and single use applicator tips.



## K163176

The Exilis XP II is a state-of-the-art radiofrequency device that enables the application of therapy by a non-invasive, high-frequency field.

The control unit of the system is fitted with a color touch screen, to facilitate use of the device. The on-screen information guides the operator through the entire therapy. For easier control, the handpiece is equipped with buttons, enabling operation of the device during therapy. Quality of the energy flow is indicated by the illuminated treatment tip.

Exilis XP II comes with the opportunity of exchangeable tips for patients greater convenience when treating various body parts.

Contact quality monitoring system is present for monitoring of the contact quality under the patch electrode. An easy-to-read handpiece display shows the selected treatment parameters.

The Exilis XP II consists of the following main components:

- microprocessor-driven control unit
- high-frequency electromagnetic energy generator
- user interface with 8.4" color touch screen
- applicator for an application of radiofrequency
- exchangeable applicator tips to treat various body parts

### Indications for Use

The Exilis XP II RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.

The Exilis XP II massage device is intended to provide a temporary reduction in the appearance of cellulite.

### Non-clinical Testing

The Exilis XP II device has been thoroughly evaluated for electrical safety. The Exilis XP II has been found to conform with applicable medical device safety standards. The system complies with the following standards:

ISO 14971 – Medical devices – Application of risk management to medical devices

IEC 62304 – Medical Device Software – Software Life Cycle Processes

#### Medical Electrical Equipment

IEC 60601-1 General requirements for safety

IEC 60601-1-2 Electromagnetic compatibility–Requirements and Tests



**K163176**

- IEC 60601-2-2 Particular requirements for the basic safety and essential performance of high frequency surgery equipment and high frequency surgical accessories
- ISO 10993-1 Evaluation and testing within a risk management process
- ISO 10993-5 Biological Evaluation of Medical Devices–Tests for In Vitro toxicity
- ISO 10993-10 Biological Evaluation of Medical Devices–Test for Irritation and Skin Sensitization

**Clinical testing**

The substantial equivalence determination for the Exilis XP II system is not based upon clinical performance testing. The device safety and efficacy was demonstrated by comparison of technical characteristics between the Exilis XP II and compared to the predicate device.

**Summary of Clinical and Non-clinical testing**

Non-clinical test have been conducted to evaluate the Exilis SP II performance, and results confirm that the device performs as intended and in a similar manner compared to the predicate. Thus, the Exilis XP II is substantially equivalent to the predicate devices.

**Comparison with the Predicate Device**

Device Name	Exilis XP II	Exilis XP
<b>Manufacturer</b>	BTL Industries, Inc.	BTL Industries, Inc.
<b>510(k) Number</b>	Current Submission	K143040
<b>Product Code</b>	<u>General &amp; Plastic Surgery</u> 21 CFR 878.4400	<u>General &amp; Plastic Surgery</u> 21 CFR 878.4400
<b>Regulation</b>	• PBX, Electrosurgical, Cutting & Coagulation & Accessories	• PBX, Massager, Vacuum, Radio Frequency Induced Heat
<b>Indications for Use</b>	The Exilis XP II RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The Exilis XP II massage device is intended to provide a temporary reduction in the appearance of cellulite.	The Exilis XP RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The Exilis XP massage device is intended to provide a temporary reduction in the appearance of cellulite.



**K163176**

<b>Device Name</b>	<b>Exilis XP II</b>	<b>Exilis XP</b>
<b>Manufacturer</b>	BTL Industries, Inc.	BTL Industries, Inc.
<b>510(k) Number</b>	Current Submission	K143040
<b>Device Technologies</b>	Application of the heat to the tissue via RF energy. Massaging of body parts with massage device.	Application of the heat to the tissue via RF energy. Massaging of body parts with massage device.
<b>Electrical Protection</b>	Class II, BF	Class II, BF
<b>Color Touch Screen</b>	8.4" (21.5cm)/640x480 pixel	8.4" (21.5cm)/640x480 pixel
<b>Exchangeable Applicator Tips Available</b>	Yes	No
<b>Maximum Output Power</b>	120 W	120 W
<b>Effective Treatment Temperature</b>	40 - 45 °C	40 - 45 °C
<b>Modes of Operation</b>	Monopolar	Monopolar
<b>Output Frequency</b>	3.25 MHz	3.25 MHz
<b>Energy Source</b>	100 - 240 VAC, max 4A, 50-60 Hz	100 - 240 VAC, max 4A, 50-60 Hz
<b>Dimensions (W x H x D)</b>	16" x 10.6" x 11.9" (41 cm x 22 cm x 18 cm)	16" x 10.6" x 11.9" (41 cm x 22 cm x 18 cm)
<b>Weight</b>	16 lb (7.3 kg)	16 lb (7.3 kg)

**Substantial Equivalence**

Based upon the intended use and technical information provided in this pre-market notification, the Exilis XP II device has been shown to be substantially equivalent to currently marketed predicate device.

**Conclusion**

Based on the aforementioned information, the changes in Exilis XP II do not raise any new questions of safety and effectivity and the device is substantially equivalent to the identified predicate device.